Company: PTPI
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001104659-25-025104
Chunk: 26

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 26
---
 a complete description of the terms and conditions of the Series A Warrants.

Duration and Exercise Price

Each Series A Warrant is exercisable
for 0.25 share of Common Stock, has an exercise price equal to $0.48 per share, will become exercisable on (the “Initial
Exercise Date”) the first trading day following the date of the requisite stockholder approval (the “Stockholder
Approval”, and such date, the “Stockholder Approval Date”) and will expire on the fifth anniversary of such
Initial Exercise Date. The exercise price and number of shares of Common Stock issuable upon exercise of the Series A Warrants
is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our
Common Stock and the exercise price. The Series A Warrants were issued separately from the shares of Common Stock and/or
Pre-Funded Warrants sold in the Offering and may be transferred separately immediately thereafter.

Exercise Price Adjustments

In addition, and subject to certain exemptions,
if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right
to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares
of Common Stock, at an effective price per share less than the exercise price of the Series A Warrants then in effect, the exercise
price of the Series A Warrants will be reduced to the lower of such price or the lowest VWAP during the five consecutive trading
days immediately following such dilutive issuance or announcement thereof (subject to a floor price of $0.1465 prior to the Stockholder
Approval Date and a floor price of $0.0586 on the Stockholder Approval Date (such floor price then in effect, the “Series A Floor
Price”) and the number of shares issuable upon exercise of the Series A Warrants will be proportionately adjusted such that
the aggregate exercise price will remain unchanged (the “Dilutive Issuance Provision”).

If at any time on or after the date of issuance there occurs any stock
split, stock dividend, stock combination recapitalization, reverse stock split, or other similar transaction involving our Common Stock
and the lowest daily VWAP during the period commencing five consecutive trading days immediately preceding and the five consecutive trading
days commencing on the date of such event is less than the exercise price of